Navigation Links
Cephalon Reported Financial Results for the Second Quarter of 2011
Date:8/2/2011

4,160Total equity

3,381,3382,667,592$ 5,753,086$
4,891,833CEPHALON, INC. AND SUBSIDIARIESCONSOLIDATED STATEMENTS OF CASH FLOWS(In thousands)(Unaudited)Six Months Ended June 30,20112010CASH FLOWS FROM OPERATING ACTIVITIES:Net income

$  326,802$  192,730Adjustments to reconcile net income to net cash provided by operating activities:Deferred income tax expense (benefit)

52,156(18,059)Shortfall tax benefits from stock-based compensation

(331)(559)Depreciation and amortization

93,389106,724Stock-based compensation expense

16,95021,630Amortization of debt discount and debt issuance costs

32,77635,692Changes in fair value of investments

(264,208)-Loss (gain) on foreign exchange contracts

(5,089)9,499Impairment and loss (gain) on sale of fixed assets

54,056-Other

23,0903,752Changes in operating assets and liabilities:Receivables

(37,532)(25,581)Inventory

5,64618,985Other assets

1,2079,474Accounts payable, accrued expenses and deferred revenues

(11,445)23,955Other liabilities

(65,462)(189)Net cash provided by operating activities

222,005378,053CASH FLOWS FROM INVESTING ACTIVITIES:Purchases of property and equipment

(28,049)(22,997)Proceeds from sale of property and equipment

818-Cash balance from consolidation of variable interest entity

15,513-Acquisition of Mepha net of cash acquired (549,463)Acquisition of Gemin X, net of cash acquired

(184,198)Acquisition of ChemGenex, net of cash acquired

(179,931)Purchases of investments

(135,453)(60)(Cash settlements of) proceeds from foreign exchange contracts

7,111(9,499)Net cash used for investing activities

(504,189)(582,019)CASH FLOWS FROM FINANCING ACTIVITIES:Proceeds from sale of common stock

349-Proceeds from exercises of common stock options

133,70314,370Windfall tax benefits from stock-based compensation

12,060-Ac
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Cephalon Quarterly Conference Call Invitation
2. Cephalon Concludes All Outstanding Federal and State Government Investigations into the Companys Sales and Promotional Practices
3. $425 Million Cephalon Civil Settlement and Criminal Fine; In Americas Largest
4. Cephalon Launches National Consumer Awareness Initiative on Appropriate Use of Prescription Opioid Medications
5. Cephalon and Eurand Announce Notification of Generic Filing for Cyclobenzaprine Hydrochloride Extended-Release Capsules
6. Cephalon Reports Another Strong Quarter
7. Cephalon, Inc. to Webcast Analyst Day
8. Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
9. Cephalon Exercises Option to License Worldwide Rights to ImmuPharma Product, Lupuzor
10. Cephalon Appoints Sarma P. Duddu as General Manager and Vice President of Drug Delivery Technologies for CIMA LABS
11. Cephalons New Product Launches Pace Record 2008 Sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... , May 21, 2015  Prima Biomed Ltd. ... that is striving to become a leader in the ... recently announced that the final CVac data from the ... a clear trend for a clinically meaningful improvement in ... second remission patients. In the group of ...
(Date:5/21/2015)... Imagine being able to probe and truly ... Being able to read faces and enjoy genuine invisible ... their thoughts and actions like never before. Use ... unique abstract paintings and video, or, play a completely ... as it creates action, dialog, and outcomes based on ...
(Date:5/21/2015)...  CytRx Corporation (NASDAQ: CYTR ), a ... today announced positive updated results from its ongoing ... treatment of unresectable glioblastoma multiforme (GBM), a deadly ... is designed to investigate the preliminary efficacy and ... progressed following prior treatment with surgery, radiation and ...
(Date:5/21/2015)... - RepliCel Life Sciences Inc. (TSX.V: RP) (OTCQB: ... on the development of autologous cell therapies, announced ... Society for Cellular Therapy (ISCT) on RepliCel,s autologous ... a Phase 1/2 clinical trial.  The presentation, taking ... PM to 7:00 PM local time, will review ...
Breaking Biology Technology:Correction Continues after Big Move - BrokerBank Securities, Inc. 25 Days to Meet ARGUS - The World's First Contactless Emotions Scanner 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3
... Renowned Clinical Authorities to Advise on Development of New Drug ... Candidate to Treat Autoimmune Disease ... a privately-held drug development company, announced today that it,has appointed ... a peptide fusion protein licensed from Amgen in December 2007 ...
... Merchandisers to Sell Unique Back and Other Pain ... ... Sheets: BIEL), announced today that it has signed a,sales, marketing and distribution ... leading Canadian sales and marketing,distributor of natural health products, medical devices, and ...
... BRISBANE, Australia, Feb. 5 Xenome Limited today,announced ... Company,s Chief,Executive Officer. Dr. Nisbet will also join ... previously worked in senior management and executive,roles in ... Meditech Research Ltd, Millennium Pharmaceuticals Inc,and CSL Ltd. ...
Cached Biology Technology:Anthera Pharmaceuticals Forms Scientific Advisory Board 2BioElectronics Announces Canadian Retail Product Launch 2Xenome Names Ian T. Nisbet, PhD as Chief Executive Officer 2
(Date:5/19/2015)... Fingerprint Cards (FPC) has received an order for ... from one if its module partners. Deliveries are planned to ... the sensors will be used by smartphone manufacturers in ... amount to 740 MSEK to date. In addition to previously ... number of smaller orders not separately communicated amounting to more ...
(Date:5/14/2015)... 2015  Verificient Technologies, Inc., a technology ... remote proctoring, announced a new alliance partnership ... creator of the Canvas Learning Management System ... will benefit from the seamless integration of ... a fully integrated multifactor biometrics behavioral application, ...
(Date:5/8/2015)... , May 8, 2015 Synaptics Inc. (NASDAQ: ... announced that members of the executive management team will present ... Annual Technology, Media and Telecom Conference Date: May 18, ... Boston, MA Cowen and ... Time: 2:45pm ET Location: The New York Palace Hotel, ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Synaptics to Present at Upcoming Investor Conferences 2
... researchers led by Richard Van Emmerik at the University ... through the Navy Health Research Center in the Department ... load carried by soldiers, which can be even heavier ... and ability to carry out missions. "Load is ...
... This press release is available in German . ... tunicate maize, the maize kernels on the cob are not ,naked, ... scientists from the Max Planck Institute for Plant Breeding Research in ... the activity of a leaf gene in the maize cob that ...
... /PRNewswire-iReach/  -- Global Information Inc. is announces limited time ... important Boston healthcare conferences: Next-Gen Kinase ... rapidly maturing kinase inhibitors field will gather to explore ... Next-Gen Kinase Inhibitors Conference in Cambridge, MA. ...
Cached Biology News:Kinesiology team gets $975,000 Defense grant to study effects of heavy loads on soldiers 2Pod corn develops leaves in the inflorescences 2Pod corn develops leaves in the inflorescences 3Attendees Save Up To $800 on Boston-area Pharmaceutical and Healthcare Conferences, Early Bird Discounts Expiring April 27 2Attendees Save Up To $800 on Boston-area Pharmaceutical and Healthcare Conferences, Early Bird Discounts Expiring April 27 3
... flask clips, purpose-designed to firmly retain glassware, ... are equipped with a top retainer spring; ... bottom retainer spring, and silicon tubing spring ... Clips include the required mounting screws., ...
... shaker flask clips, purpose-designed to firmly retain ... clips are equipped with a top retainer ... a bottom retainer spring, and silicon tubing ... glassware. Clips include the required mounting ...
Anti-Tissue Trans-glutaminase (IgA) EIA Sample Size: 10 l...
... Heavy duty stainless-steel shaker flask clips, purpose-designed ... speeds. All clips are equipped with ... 1L.) also include a bottom retainer spring, ... scratching of expensive glassware. Clips include ...
Biology Products: